Catalog No.
PMD47901
Species reactivity
Mouse
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Mouse FGFR2 (Arg409-Asp702).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
K-sam, KSAM, CD332, Keratinocyte growth factor receptor, Fibroblast growth factor receptor 2, FGFR-2, FGFR2, KGFR, BEK
Purification
Purified by antigen affinity column.
Accession
B7ZWP2
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Multicenter observational study to characterize fibroblast growth factor receptor 2 fusions or rearrangements in patients with advanced/metastatic cholangiocarcinoma., PMID:40317840
The Role of Fibroblast Growth Factor Receptor 2 as A Prognostic Biomarker in Colorectal Adenocarcinoma., PMID:40302086
Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer., PMID:40216702
Identification of potent biparatopic antibodies targeting FGFR2 fusion-driven cholangiocarcinoma., PMID:40014401
Nivolumab Combined with Chemotherapy in FGFR2 and PD-L1 Co-Expressing Metastatic Gastric Cancer: A Prospective Phase 2 NIVOFGFR2 Study., PMID:39799264
Expression of therapy target molecules in esophagogastric junction and Barrett's adenocarcinoma., PMID:39663311
Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors., PMID:39583123
FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development., PMID:39536791
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer., PMID:39513959
Novel deoxyhypusine synthase (DHPS) inhibitors target hypusination-induced vasculogenic mimicry (VM) against malignant melanoma., PMID:39393437
Identification of potent biparatopic antibodies targeting FGFR2 fusion driven cholangiocarcinoma., PMID:39345400
Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art., PMID:39315517
Deciphering the FGFR2 Code: Innovative Targets in Gastric Cancer Therapy., PMID:39195304
Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin-18 isoform 2 splicing variants in gastric cancer and other solid tumours., PMID:38877656
Do Fibroblast Growth Factor Receptor (FGFR) 2 and 3 Proteins Play a Role in Prognosis of Invasive Urothelial Bladder Carcinoma?, PMID:38864084
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis., PMID:38861192
Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer., PMID:38791079
State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care., PMID:38771996
Tumor formation at ileocecal junction associated with interleukin-1β upregulation in aryl hydrocarbon receptor-deficient mouse., PMID:38769691
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial., PMID:38745009
Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept., PMID:38689741
Targeted and immunotherapy for the management of advanced urothelial carcinoma of the bladder., PMID:38679913
New therapeutic target molecules for gastric and gastroesophageal junction cancer., PMID:38630383
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations., PMID:38627238
Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience., PMID:38606821
Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter., PMID:38491511
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions., PMID:38424198
Advances in targeted therapy for gastric cancer based on tumor driver genes., PMID:38413217
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial., PMID:38308771
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7., PMID:38154497
Precision Medicine in Urothelial Carcinoma: Current Markers to Guide Treatment and Promising Future Directions., PMID:38085403
Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy., PMID:37675102
Targeting of human fibroblast growth factor receptor 2 by a novel specific nanobody., PMID:37452673
FGF10/FGFR2 Signaling: Therapeutically Targetable Vulnerability in Ligand-responsive Cholangiocarcinoma Cells., PMID:37369494
Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion., PMID:37280393
[Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization]., PMID:37272439
Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination., PMID:36751001
Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models., PMID:36729099
Chondrosarcoma with Target-Like Chondrocytes: Update on Molecular Profiling and Specific Morphological Features., PMID:36689318
Aberrations in FGFR1, FGFR2, and RIP5 Expression in Human Congenital Anomalies of the Kidney and Urinary Tract (CAKUT)., PMID:36555181
[Oesogastric cancer - new therapeutic targets]., PMID:36371284
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study., PMID:36244398
Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments., PMID:36238135
IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target., PMID:36180600
Identification and characterization of FGFR2+ hematopoietic stem cell-derived fibrocytes as precursors of cancer-associated fibroblasts induced by esophageal squamous cell carcinoma., PMID:35941662
Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer., PMID:35406567
T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases., PMID:35395222
The dawn of precision medicine in diffuse-type gastric cancer., PMID:35281349
Gene fusions in gastrointestinal tract cancers., PMID:35239225
Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways., PMID:35218764
For research use only. Not for human or drug use.
